Alzheimer's disease (AD) is the most common form of dementia and may contribute to 60–
70% of cases. Worldwide, around 50 million people suffer from dementia and the prediction …

Alzheimer's disease is one of the most commonly diagnosed cases of senile dementia in the
world. It is an incurable process, most often leading to death. This disease is multifactorial …

Alzheimer's disease (AD) is the most frequent case of neurodegenerative disease and is
becoming a major public health problem all over the world. Many therapeutic strategies …

Amyloid-β (Aβ) plaques and aggregated tau are two core mechanisms that contribute to the
clinical deterioration of Alzheimer's disease (AD). Recently, targeted-Aβ plaque reduction …

The deposition of amyloid-beta (Aβ) plaques in the brain is one of the primary pathological
characteristics of Alzheimer's disease (AD). It can take place 20–30 years before the onset of …

Alzheimer's disease (AD) is an incurable, progressive neurodegenerative disorder. AD is a
complex and multifactorial disease that is responsible for 60–80% of dementia cases. Aging …

A phase II trial of the tau antibody semorinemab indicates that it has no clinical benefit in the
earliest stages of Alzheimer disease. The repeated finding that antibody-mediated …

Alzheimer's disease (AD) is a rapidly growing epidemic with a heavy social and economic
burden. Evidence suggests that systemic inflammation, dysregulation of the immune …

Alzheimer's disease (AD) is the most prevalent form of dementia, characterized by the
presence of plaques of amyloid beta and Tau proteins. There is currently no permanent cure …

Aging is a major risk factor for numerous chronic diseases. Vaccination offers a promising
strategy to combat these age-related diseases by targeting specific antigens and inducing …